Is ANXIETY a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ANXIETY.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 90 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ANXIETY to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ANXIETY. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ANXIETY, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ANXIETY. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ANXIETY ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ANXIETY: 90
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ANXIETY is a reported side effect: 2.7035%

FDA reports of any drug causing ANXIETY : 107014
Average percentage for all medicated patients where ANXIETY is reported as a complication: 0.6707%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ANXIETY:

FOSAMAX (14421 patients)
TRASYLOL (11840 patients)
VIOXX (10580 patients)
CHANTIX (8909 patients)
YAZ (8332 patients)
ZOMETA (8240 patients)
YASMIN (7753 patients)
ASPIRIN (7409 patients)
ACCUTANE (7091 patients)
SEROQUEL (5765 patients)
XANAX (5179 patients)
LASIX (4962 patients)
AREDIA (4949 patients)
ZOLOFT (4587 patients)
LIPITOR (4494 patients)
PAXIL (4434 patients)
AMBIEN (3863 patients)
PREDNISONE (3830 patients)
NEURONTIN (3816 patients)
SYNTHROID (3803 patients)
LISINOPRIL (3794 patients)
NEXIUM (3763 patients)
COUMADIN (3514 patients)
HEPARIN (3478 patients)
OXYCONTIN (3348 patients)
PRILOSEC (3266 patients)
LEXAPRO (3247 patients)
CYMBALTA (3132 patients)
LEVAQUIN (3123 patients)
METOCLOPRAMIDE (3120 patients)
CELEBREX (3046 patients)
MAGNEVIST (3044 patients)
ATIVAN (2991 patients)
PROTONIX (2983 patients)
DIGOXIN (2916 patients)
IBUPROFEN (2829 patients)
ZOCOR (2786 patients)
ALBUTEROL (2731 patients)
ATENOLOL (2728 patients)
VICODIN (2725 patients)
LORAZEPAM (2714 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (2701 patients)
PLAVIX (2578 patients)
NITROGLYCERIN (2523 patients)
LYRICA (2498 patients)
EFFEXOR (2465 patients)
PERCOCET (2421 patients)
PREVACID (2410 patients)
HYDROCHLOROTHIAZIDE (2410 patients)
TOPROL-XL (2361 patients)
KLONOPIN (2321 patients)
NORVASC (2311 patients)
FUROSEMIDE (2290 patients)
ALPRAZOLAM (2258 patients)
PROZAC (2246 patients)
CLONAZEPAM (2218 patients)
WELLBUTRIN (2146 patients)
PREMARIN (2054 patients)
OMEPRAZOLE (2027 patients)
SIMVASTATIN (2017 patients)
SINGULAIR (2006 patients)
AVONEX (1982 patients)
EFFEXOR XR (1957 patients)
AMOXICILLIN (1933 patients)
CELEXA (1927 patients)
FENTANYL (1923 patients)
DURAGESIC-100 (1919 patients)
ACETAMINOPHEN (1915 patients)
POTASSIUM CHLORIDE (1839 patients)
DIAZEPAM (1836 patients)
LORTAB (1834 patients)
DEXAMETHASONE (1811 patients)
GABAPENTIN (1799 patients)
ZOFRAN (1786 patients)
OXYCODONE HCL (1739 patients)
OMNISCAN (1738 patients)
HEPARIN SODIUM INJECTION (1730 patients)
INSULIN (1721 patients)
ADVAIR DISKUS 100/50 (1717 patients)
LEVOTHYROXINE SODIUM (1681 patients)
VANCOMYCIN (1677 patients)
FOLIC ACID (1637 patients)
PROTAMINE SULFATE (1610 patients)
DECADRON (1597 patients)
MORPHINE (1582 patients)
ACETYLSALICYLIC ACID SRT (1567 patients)
FLEXERIL (1526 patients)
ZYPREXA (1524 patients)
VALIUM (1509 patients)
COREG (1502 patients)
ZYRTEC (1427 patients)
TYSABRI (1423 patients)
TRAZODONE HCL (1403 patients)
REGLAN (1400 patients)
VITAMIN D (1399 patients)
DIOVAN (1393 patients)
RED BLOOD CELLS (1384 patients)
VERSED (1383 patients)
METOPROLOL TARTRATE (1376 patients)
MULTI-VITAMINS (1375 patients)
CALCIUM (1369 patients)
LOPRESSOR (1363 patients)
ZITHROMAX (1340 patients)
ZANTAC (1321 patients)
PAROXETINE HCL (1317 patients)
METFORMIN HCL (1316 patients)
RISPERDAL (1292 patients)
CHEMOTHERAPEUTICS NOS (1283 patients)
AVANDIA (1276 patients)
ALENDRONATE SODIUM (1255 patients)
FORTEO (1254 patients)
PRISTIQ (1246 patients)
CIPROFLOXACIN (1242 patients)
HYDROCODONE (1215 patients)
CEPHALEXIN (1182 patients)
CITALOPRAM HYDROBROMIDE (1177 patients)
LOVENOX (1175 patients)
FEMARA (1170 patients)
FOSAMAX PLUS D (1157 patients)
OPTIMARK (1147 patients)
BENADRYL (1145 patients)
LAMICTAL (1144 patients)
CLINDAMYCIN (1126 patients)
WARFARIN SODIUM (1124 patients)
LANTUS (1123 patients)
ALLOPURINOL (1113 patients)
ALLEGRA (1112 patients)
LIDOCAINE (1110 patients)
CRESTOR (1102 patients)
REMICADE (1102 patients)
TAMOXIFEN CITRATE (1097 patients)
PREDNISONE TAB (1095 patients)
METHOTREXATE (1091 patients)
BEXTRA (1089 patients)
AVELOX (1085 patients)
HUMIRA (1077 patients)
THALIDOMIDE (1076 patients)
MOTRIN (1076 patients)
PROMETHAZINE (1070 patients)
FLONASE (1069 patients)
GLUCOPHAGE (1068 patients)
DILAUDID (1066 patients)
COLACE (1065 patients)
TOPAMAX (1059 patients)
ELAVIL (1048 patients)
COZAAR (1043 patients)
CLONIDINE (1042 patients)
COMPAZINE (1035 patients)
NAPROXEN (1030 patients)
TEMAZEPAM (1012 patients)
TRAMADOL HCL (997 patients)
METOPROLOL (984 patients)
[THERAPY UNSPECIFIED] (984 patients)
ARANESP (978 patients)
ASCORBIC ACID (977 patients)
ACTONEL (974 patients)
DEPAKOTE (966 patients)
MIRTAZAPINE (961 patients)
AZITHROMYCIN (960 patients)
VITAMIN E (959 patients)
ARIMIDEX (956 patients)
MULTIHANCE (947 patients)
SPIRONOLACTONE (947 patients)
PEPCID (943 patients)
MULTI-VITAMIN (942 patients)
PROHANCE (937 patients)
MORPHINE SULFATE (937 patients)
CIPRO (936 patients)
ABILIFY (935 patients)
SPIRIVA (934 patients)
RADIATION THERAPY (932 patients)
HYDROCODONE BITARTRATE (913 patients)
TAXOTERE (911 patients)
AMITRIPTYLINE HCL (908 patients)
SOMA (904 patients)
EPOGEN (903 patients)
KEFLEX (902 patients)
TYLENOL (901 patients)
MIRAPEX (899 patients)
PERIDEX (896 patients)
ENBREL (883 patients)
TYLENOL (CAPLET) (873 patients)
AMIODARONE HCL (871 patients)
BONIVA (868 patients)
PLATELETS (864 patients)
REMERON (861 patients)
ULTRAM (854 patients)
FLUOXETINE (852 patients)
RANITIDINE (847 patients)
RESTORIL (841 patients)
ALTACE (835 patients)
CLARITIN (832 patients)
XELODA (828 patients)
FLUCONAZOLE (826 patients)
CALCIUM (UNSPECIFIED) (825 patients)
ANCEF (823 patients)
OXYCODONE (809 patients)
EPINEPHRINE (806 patients)
GEODON (805 patients)
FLOMAX (800 patients)
LEVOXYL (799 patients)
CHLORHEXIDINE GLUCONATE (799 patients)
ACIPHEX (797 patients)
ACTOS (795 patients)
FLAGYL (789 patients)
CALCIUM CARBONATE (782 patients)
DOXYCYCLINE (778 patients)
MANNITOL (773 patients)
NUVARING (769 patients)
CARDIZEM (769 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ANXIETY and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.